II. Epidemiology
III. Pathophysiology
- Although there are many Chronic Complications of ICU Care, Post-Covid effects are often seen in less severe cases
- Proposed Mechanisms
- Residual tissue injury from acute infection
- Persistent smoldering viral activity from a host reservoir
- Hyperinflammatory state complications (Multisystem Inflammatory Syndrome)
- Immune dysfunction
- Preexisting comorbid conditions that are unmasked or provoked by Covid infection
IV. Risk Factors
- Age over 50 years old
- Female gender
- Obesity
- Severe acute infection (or more than 5 symptoms in the first week of illness)
- Unvaccinated or incompletely vaccinated with Covid19 Vaccine (<3 Vaccine doses)
- Type 2 Diabetes Mellitus
- Immunocompromised patient
- Hypertension
- Psychiatric Conditions
- Earlier strains of Covid
- Azzolini (2022) JAMA 328(7): 676-8 [PubMed]
V. Symptoms
-
General
- Fatigue (<58%)
- Similar to Chronic Fatigue Syndrome
- Common in post-covid symptoms >6 months
- Night Sweats (<24%)
- Appetite change (<17%)
- Weight loss (<21%)
- Fatigue (<58%)
- Cardiopulmonary
- Chest Pain (<16%)
- Palpitations (<14%)
- Dyspnea (<30%)
- Cough (<15%)
- Autonomic Dysfunction (e.g. Postural Orthostatic Tachycardia Syndrome or POTS Syndrome)
- POTS Syndrome demonstrates Orthostatic Intolerance with Tachycardia, without significant Orthostatic Hypotension
- Mast Cell Activation Syndrome (Hypotension, Palpitations, Urticaria, Wheezing, Rhinitis, Pharyngitis, Conjunctivitis)
- Decreased Exercise tolerance (<15%)
- Post-exertional malaise
- Common, hallmark symptom in post-covid symptoms >6 months
- Exhaustion and prolonged recovery, requiring days to weeks, starting 12 to 72 hours after activity
- Musculoskeletal
- Decreased mobility (<20%)
- Arthralgias and myalgias (<14%)
- Neurologic
- Headache (12 to 44%)
- Cognitive dysfunction (common in post-covid symptoms >6 months)
- Attention disorder, difficulty concentrating or brain fog (<27%)
- Memory deficit (<19%)
- Altered taste, Ageusia, parageusia, dysguesia (<23%)
- Altered Sense of Smell, Anosmia or Parosmia (<21%)
- Skin
- Alopecia (<25%)
- Psychiatric
- Anxiety (<30%)
- Depression (<23%)
- Post-Traumatic Stress Disorder (<13%)
- Insomnia or other sleep disorder (<27%)
VI. Associated Conditions
- Respiratory
- DLCO Decreased on Pulmonary Function Testing
- Decreased lower respiratory Muscle Strength
- Persistently abnormal CT Chest
- Huang (2020) Respir Res 21(1):163 +PMID: 32600344 [PubMed]
- Lerum TV (2020) Eur Respir J +PMID: 33303540 [PubMed]
- Cardiovascular
VII. Labs
-
General Testing in Most Cases (Identify Reversible Causes)
- Complete Blood Count
- Comprehensive Metabolic Panel
- Serum Magnesium
- C-Reactive Protein
- Erythrocyte Sedimentation Rate (ESR)
- Serum Ferritin
- Thyroid Stimulating Hormone (TSH)
- Serum Vitamin D
- Serum Vitamin B12
-
Autonomic Dysfunction Additional Testing (e.g. POTS Syndrome)
- Orthostatic Blood Pressure and pulse
- Electrocardiogram (EKG)
- Consider Gluten Sensitive Enteropathy testing
- Consider Echocardiogram
- Consider autonomic reflex testing
- Consider ambulatory Heart Rate monitoring (e.g. zio monitor)
- Neurocognitive Additional Testing (e.g. Brain Fog)
- See Cognitive Impairment
- Cognitive assessment tools (e.g. Montreal Cognitive Assessment)
- Consider Neuropsychological Testing
- Consider Thiamine replacement
- Consider MRI Brain
-
Dyspnea Additional Testing
- Chest XRay
- B-Type Natriuretic Peptide (BNP)
- Pulmonary Function Tests
- Electrocardiogram (EKG)
- Consider D-Dimer
- Consider CT Chest
- Consider Sleep Study for Obstructive Sleep Apnea (if suspected by history)
- Consider Echocardiogram
- Consider home Pulse Oximetry
- Consider Cortisol
- Chronic Fatigue Additional Testing
- Functional Capacity Testing
- Consider Respiratory Additional Testing as above
- Consider Antinuclear Antibody testing
-
Mast Cell Activation Additional Testing (Hypotension, Palpitations, Urticaria, Wheezing, Rhinitis, Pharyngitis, Conjunctivitis)
- Serum Tryptase (baseline and within <4 hours of symptom onset)
- N-Methylhistamine 24 hour Urine Collection
- Prostaglandin D2 24 hour Urine Collection
VIII. Differential Diagnosis
- Chronic Complications of ICU Care (or prolonged illness or hospitalization)
- New illness
- Exacerbation of comorbid conditions
- Chronic Kidney Disease
- Diabetes Mellitus
- Chronic lung disease (e.g. Asthma, COPD)
- Cardiomyopathy (e.g. CHF)
- Mood Disorders (e.g. Major Depression, Anxiety Disorder)
- Altered Smell or Taste
-
Dyspnea
- See Dyspnea Causes
- Obstructive Lung Disease (Asthma, COPD)
- Restrictive Lung Disease (e.g. pulmonary fibrosis)
- Cardiomyopathy (e.g. Congestive Heart Failure, Myocarditis)
- Pneumonia
- Coronary Artery Disease
- Pulmonary Embolism
- Anemia
- Autonomic Dysfunction (Dysautonomia)
- Mast Cell Activation Syndrome (Hypotension, Palpitations, Urticaria, Wheezing, Rhinitis, Pharyngitis, Conjunctivitis)
- Cognitive Dysfunction
- Chronic Fatigue Syndrome
IX. Diagnosis
X. Management
-
General
- Goals of management is improved function and quality of life
- Lifestyle Interventions (non-medication therapy)
- Limit Alcohol and Caffeine
- Tobacco Cessation
- Insomnia Nonpharmacologic Management
- Meditation and MindfulnessExercises
- Multi-specialty support
- Support groups
- Physical Therapy
- Specialists (cardiology, pulmonology, ent) as needed
- Follow-up every 2-3 months
- Altered Smell or Taste
- See Smell Dysfunction
- See Taste Dysfunction
- Smell Training
- No treatment (e.g. Intranasal Steroids) found effective in speeding olfactory recovery
- Improves or resolves more quickly than other causes of Olfactory Dysfunction
- Resolution by 7 days in a majority of patients and by 3 months in 80%
- Course prolonged in more severe disease
- Ferrell (2022) Eur Arch Otorhinolaryngol 279(9): 4633-40 [PubMed]
-
Autonomic Dysfunction (Dysautonomia)
- See Autonomic Dysfunction
- Eat smaller, more frequent meals
- Increase volume status
- Consider increased dietary salt when appropriate
- Consider Compression Stockings
- Sleep with head of bed elevated
- Perform Isometric Exercises
- Avoid triggers of Orthostatic Intolerance (e.g. excessive heat, Alcohol)
- Consider medication management starting at low dose and titrating as needed (e.g. Propranolol, Fludrocortisone, Midodrine)
- Local expert Consultation recommended
- Cognitive dysfunction
- Neuropsychiatric Consultation
- Eliminate contributing factors (e.g. Polypharmacy, medications impacting attention)
- Ensure adequate sleep
- Consider neurology Consultation
- Consider occupational therapy
- Consider speech pathologist
- Gradual return to cognitive activities
-
Dyspnea
- Pulmonary Rehabilitation and breathing Exercises
- Gradual return to activity
-
Chronic Fatigue Syndrome
- Lifestyle changes (adequate sleep, Healthy Diet, adequate hydration)
- Energy conservation (e.g. 4Ps - Plan, Pace, Prioritize, Position)
- Avoid relapse triggers (emotional stress, strenuous activity)
- Gradual return to activity
- Mast Cell Activation Syndrome (Hypotension, Palpitations, Urticaria, Wheezing, Rhinitis, Pharyngitis, Conjunctivitis)
XI. Prognosis
- Symptom peak timing may predict duration
- Recovery by 90 days: Symptoms peak at 2 weeks
- Not recovered by 90 days: Symptoms peak at 2 months
- Relapses after 6 months (Fatigue, post-exertional malaise, cognitive dysfunction) have common triggers
- Physical Activity or Exercise
- Emotional stress
- Cognitive activity
- Patients should expect continued gradual improvement with periodic relapses and set backs
- Outcomes vary from patient to patient and longterm data is limited
- More than half of patients will have symptoms >6 months, but these symptoms decrease over time
- Most patients with persistent Dyspnea following covid improve without chronic lung disease
- Most patients recover from Cognitive Impairment
XII. Prevention
-
Covid-19 Vaccine
- Most effective prevention of Long COVID (pre-exposure)
-
COVID-19 Treatment
- Paxlovid started within 5 days of Covid onset may reduce the risk of developing Long COVID
XIII. Resources
- Post-Covid (CDC)
- SurvivorCorps
XIV. References
- (2023) Presc Lett 30(4): 20-1
- Alkodaymi (2022) Clin Microbiol Infect 28(5): 657-66 [PubMed]
- Fernandez (2021) Sao Paulo Med. J. 139 +PMID:33656121 [PubMed]
- Herman (2022) Am Fam Physician 106(5): 523-32 [PubMed]
- Lopez-Leon (2021) medRxiv +PMID: 33532785 [PubMed]
- Sneller (2022) Ann Intern Med 175(7): 969-79 [PubMed]
- Michelen (2021) BMJ Glob Health 6(9): e005427 [PubMed]